Impact of genetic background on nephropathy in diabetic mice

American Journal of Physiology - Renal Physiology

Volumn 290, Issue 1, 2006, Pages

  Gurley, Susan B ^a   Clare, Sharon E ^a   Snow, Kamie P ^a   Hu, Ann ^b   Meyer, Timothy W ^b   Coffman, Thomas M ^a,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Akita mice; Albuminuria; Mouse models of type I diabetes; Strain comparison; Streptozotocin

Indexed keywords

ALBUMIN; GLUCOSE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; KIDNEY STRUCTURE; MALE; MESANGIUM; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STREPTOZOCIN DIABETES; URINARY EXCRETION; ANIMAL; BLOOD; COMPARATIVE STUDY; EXPERIMENTAL DIABETES MELLITUS; GENETICS; KIDNEY; METABOLISM; MOUSE STRAIN; PATHOLOGY;

ALBUMINURIA; ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FEMALE; KIDNEY; MALE; MICE; MICE, INBRED STRAINS;

EID: 33644802764     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00204.2005     Document Type: Article

References (48)

1. Anderson S, Rennke HG, Garcia DL, and Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36: 526-536, 1989.
2. Barzilay J, Warram JH, Bak M, Laffel LM, Canessa M, and Krolewski AS. Predisposition to hypertension: risk factor for nephropathy and hypertension in IDDM. Kidney Int 41: 723-730, 1992.
3. Black BL, Croom J, Eisen EJ, Petro AE, Edwards CL, and Surwit RS. Differential effects of fat and sucrose on body composition in A/J and C57BL/6 mice. Metabolism 47: 1354-1359, 1998.
4. Bleasel AF and Yong LC. Streptozotocin induced diabetic nephropathy and renal tumors in the rat. Experientia 38: 129-130, 1982.
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, and Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001.
6. Bronson SK and Smithies O. Altering mice by homologous recombination using embryonic stem cells. J Biol Chem 269: 27155-27158, 1994.
7. Chavers BM, Bilous RW, Ellis EN, Steffes MW, and Mauer SM. Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med 320: 966-970, 1989.
8. Clark LD, Clark RK, and Heber-Katz E. A new murine model for mammalian wound repair and regeneration. Clin Immunol Immunopathol 88: 35-45, 1998.
9. Coleman DL, Kuzava JE, and Leiter EH. Effect of diet on incidence of diabetes in nonobese diabetic mice. Diabetes 39: 432-436, 1990.
10. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352: 213-219, 1998.
11. Cowie CC. Diabetic renal disease: racial and ethnic differences from an epidemiologic perspective. Transplant Proc 25: 2426-2430, 1993.
12. Dalla Vestra M, Saller A, Mauer M, and Fioretto P. Role of mesangial expansion in the pathogenesis of diabetic nephropathy. J Nephrol 14, Suppl 4: S51-S57, 2001.
13. 16a.Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development, and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
14. Doi K, Matsuzaki H, Tsuda T, and Onodera T. Rapid development of renal lesions in diabetic DBA mice infected with the D-variant of encephalomyocarditis virus (EMC-D). Br J Exp Pathol 70: 275-281, 1989.
15. Drummond K and Mauer M. The early natural history of nephropathy in type 1 diabetes. II. Early renal structural changes in type 1 diabetes. Diabetes 51: 1580-1587, 2002.
16. Fioretto P, Steffes MW, Brown DM, and Mauer SM. An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. Am J Kidney Dis 20: 549-558, 1992.
17. George M, Ayuso E, Casellas A, Costa C, Devedjian JC, and Bosch F. Beta cell expression of IGF-I leads to recovery from type 1 diabetes. J Clin Invest 109: 1153-1163, 2002.
18. Hem A, Smith AJ, and Solberg P. Saphenous vein puncture for blood sampling of the mouse, rat, hamster, gerbil, guinea pig, ferret and mink. Lab Anim 32: 364-368, 1998.
19. Hirose K, Osterby R, Nozawa M, and Gundersen HJ. Development of glomerular lesions in experimental long-term diabetes in the rat. Kidney Int 21: 889-895, 1982.
20. Ishida BY, Blanche PJ, Nichols AV, Yashar M, and Paigen B. Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H. J Lipid Res 32: 559-568, 1991.
21. Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, and Coffman TM. Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc Natl Acad Sci USA 92: 3521-3525, 1995.
22. Izumi T, Yokota-Hashimoto H, Zhao S, Wang J, Halban PA, and Takeuchi T. Dominant negative pathogenesis by mutant proinsulin in the Akita diabetic mouse. Diabetes 52: 409-416, 2003.
23. Krege JH, Hodgin JB, Hagaman JR, and Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25: 1111-1115, 1995.
24. Leiter EHGI and Flynn JC. Spontaneous Insulin Dependent Diabetes Mellitus (IDDM) in Non-obese Diabetic(NOD) Mice: Comparisons with Experimentally Induced IDDM in Experimental Models of Diabetes. Boca Raton, FL: CRC, 1999.
25. Lewis EJ, Hunsicker LG, Bain RP, and Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993.
26. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, and Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001.
27. Like AA and Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 193: 415-417, 1976.
28. Nishina PM, Verstuyft J, and Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res 31: 859-869, 1990.
29. Okazaki M, Saito Y, Udaka Y, Maruyama M, Murakami H, Ota S, Kikuchi T, and Oguchi K. Diabetic nephropathy in KK and KK-Ay mice. Exp Anim 51: 191-196, 2002.
30. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, and Kuller LH. Prevalence of complications in IDDM by sex and duration. Pittsburgh epidemiology of diabetes complications study II. Diabetes 39: 1116-1124, 1990.
31. Paigen B, Morrow A, Brandon C, Mitchell D, and Holmes P. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 57: 65-73, 1985.
32. Paik SG, Michelis MA, Kim YT, and Shin S. Induction of insulin-dependent diabetes by streptozotocin. Inhibition by estrogens and potentiation by androgens. Diabetes 31: 724-729, 1982.
33. Parekh PI, Petro AE, Tiller JM, Feinglos MN, and Surwit RS. Reversal of diet-induced obesity and diabetes in C57BL/6J mice. Metabolism 47: 1089-1096, 1998.
34. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, and Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33: 438-443, 1990.
35. Rossini AA, Appel MC, Williams RM, and Like AA. Genetic influence of the streptozotocin-induced insulitis and hyperglycemia. Diabetes 26: 916-920, 1977.
36. Rossini AA, Williams RM, Appel MC, and Like AA. Complete protection from low-dose streptozotocin-induced diabetes in mice. Nature 276: 182-184, 1978.
37. Rossini AA, Williams RM, Appel MC, and Like AA. Sex differences in the multiple-dose streptozotocin model of diabetes. Endocrinology 103: 1518-1520, 1978.
38. Sharma K, McCue P, and Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 284: F1138-F1144, 2003.
39. 41a.Sima, AAF, and Shafrir E. Animal Models of Diabetes A. Primer. Australia: Harwood Academic, 2001.
40. Simpson EM, Linder CC, Sargent EE, Davisson MT, Mobraaten LE, and Sharp JJ. Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nat Genet 16: 19-27, 1997.
41. Sowers JR, Epstein M, and Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37: 1053-1059, 2001.
42. 43a. United States Renal Data System. 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003.
43. Weibel ER. Stereological Mehtods: Practical Methods for Biological Morphometry. London, UK: Academic, 1979.
44. White P, Liebhaber SA, and Cooke NE. 129X1/SvJ mouse strain has a novel defect in inflammatory cell recruitment. J Immunol 168: 869-874, 2002.
45. Wolf J, Lilly F, and Shin SI. The influence of genetic background on the susceptibility of inbred mice to streptozotocin-induced diabetes. Diabetes 33: 567-571, 1984.
46. 46a. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development, and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290: 2159-2167, 2003.
47. Yoshioka M, Kayo T, Ikeda T, and Koizumi A. A novel locus, Mody4, distal to D7Mit189 on chromosome 7 determines early-onset NIDDM in nonobese C57BL/6 (Akita) mutant mice. Diabetes 46: 887-894, 1997.
48. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, and Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77: 1925-1930, 1986.